How many injections do you need to take a year to use Enactuzumab?

Eranatamab (Elranatamab) is a bispecific T cell-engaging antibody developed by Pfizer targeting B-cell maturation antigen (BCMA). It is mainly used to treat relapsed or refractory multiple myeloma. It achieves precise immune-mediated killing of tumor cells by simultaneously binding to the CD3 receptor on T cells and BCMA on the surface of myeloma cells. This mechanism enables it to have sustained anti-tumor activity in patients, so the frequency of administration must take into account both efficacy and safety.

In the early stages of use, enantuzumab requires incremental dose initial treatment (step-up dosing) to reduce the risk of immune-related adverse reactions such as cytokine release syndrome (CRS), and then enters the maintenance treatment phase. The generally recommended dosing frequency is subcutaneous injection once a week, with the first two low-dose escalations followed by a fixed-dose injection phase. According to the current clinical medication regimen, if the patient tolerates the treatment well and the disease control is stable, the injection frequency can be adjusted to once every two weeks around the seventh month of treatment. This flexible frequency adjustment helps reduce the burden of long-term treatment while maintaining sustained efficacy.

Therefore, in the first phase of the standard treatment course (about6 months), eractuzumab needs to be injected once a week, about 26 times; if it is changed to once every two weeks after entering the second phase, the total number of injections in one year will be about 40 times, depending on the patient's condition, tolerance and doctor's evaluation. It should be noted that each patient's response to treatment is different, and doctors may make appropriate adjustments to the frequency of injections based on individual conditions.

In summary, eractuzumab is not a long-acting preparation that can be injected only a few times a year, but a targeted immune drug that requires continuous and regular injection. The frequency of administration is a key factor in ensuring the effectiveness of treatment and managing immune side effects. It is recommended that patients strictly follow the injection plan given by their doctor for long-term management.

Reference materials:https://www.drugs.com/mtm/elranatamab.html